Alisertib (MLN8237)

目录号:S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237)是一种选择性Aurora A抑制剂,无细胞试验中IC50为1.2 nM,作用于Aurora A比作用于Aurora B选择性强200倍以上。Phase 3。

规格 价格 库存 购买数量  
RMB 1375.12 现货
RMB 983.87 现货
RMB 1725.78 现货
RMB 5505.84 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献48篇:

客户使用该产品的12个实验数据:

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017, 23(14):3756-3768. Alisertib (MLN8237) purchased from Selleck.

  • Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

    Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

  • Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

产品描述 Alisertib (MLN8237)是一种选择性Aurora A抑制剂,无细胞试验中IC50为1.2 nM,作用于Aurora A比作用于Aurora B选择性强200倍以上。Phase 3。
特性 MLN8237 是第一个口服有效的小分子Aurora A激酶选择性抑制剂。
靶点
Aurora A [1]
(Cell-free assay)
1.2 nM
体外研究

MLN8237作用于Aurora A选择性比作用于结构相关的Aurora B 高200多倍,IC50为396.5 nM, 而对205种其他激酶则没有显著活性。[1] 0.5 μM MLN8237处理MM1.S和 OPM1 细胞,抑制 Aurora A磷酸化,而不影响 Aurora B调节的组蛋白H3磷酸化。MLN8237作用于多发性骨髓瘤(MM) 细胞系,显著抑制细胞增殖,IC50为0.003-1.71 μM。在BM 基质细胞,IL-6和 IGF-1 存在时,MLN8237作用于原代MM 细胞和MM细胞系,抗增殖活性比只有MLN8237单独作用时高很多。0.5 μM MLN8237 作用于原代MM细胞和细胞系,使G2/M 期细胞提高2到6倍,且显著诱导凋亡和衰老,涉及p53, p21 和p27的上调,及 PARP,caspase 3,和 caspase 9的裂解。此外, MLN8237和 Dexamethasone联用具有协同作用,具有强抗MM 功效, 而和Doxorubicin 及Bortezomib联用则具有另外的功能。[2] 0.5 μM MLN8237处理 FLO-1, OE19, 和OE33 食管腺癌细胞系,抑制集落形成,且显著提高多倍体细胞百分数,随后提高G1期细胞百分数,而与 Cisplatin (2.5 μM)联用则效果进一步提高,与单独用药相比,诱导产生更多, TAp73β, PUMA, NOXA, cleaved caspase-3, 和cleaved PARP。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGSw[HYxNjVizszN MX63NkBp MWTEUXNQ NXfSR5lJUUN3ME2wMlA1KM7:TR?= M3PRUlI3OTN4Nki0
LS174T M1THeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\2Zm8xNjVizszN NHHtdYs4OiCq NGHVdJlFVVOR MXfJR|UxRTBwMEWg{txO M3S0OVI3OTN4Nki0
T84 NWrMUYQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP5VZNpOC53IN88US=> M{XjbFczKGh? NHvKTVFFVVOR MWrJR|UxRTBwMEmg{txO MorGNlYyOzZ4OES=
LS180 M122NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYewMlUh|ryP MUi3NkBp MWDEUXNQ NWrkUm1EUUN3ME2xJO69VQ>? NV3rPI45OjZzM{[2PFQ>
SW948 Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPJSGNsOC53IN88US=> Ml7IO|IhcA>? NV61Top6TE2VTx?= NFXBNnFKSzVyPUGg{txO M3X4R|I3OTN4Nki0
HCT15 NYm1eIRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rr[|AvPSEQvF2= M2nSXVczKGh? M3HXUGROW09? NHzme5ZKSzVyPECuOEDPxE1? MlPsNlYyOzZ4OES=
DLD-1 M3y2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XYfVAvPSEQvF2= MV63NkBp NGrEbWNFVVOR NUSweJBSUUN3MEywMlgh|ryP MWqyOlE{PjZ6NB?=
MIP-101 M{\0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH1NE42KM7:TR?= MWC3NkBp MmjSSG1UVw>? MVvJR|UxRTFizszN NYPoZWxKOjZzM{[2PFQ>
SNU1544 NYL0cWVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fF[FAvPSEQvF2= MYW3NkBp MYTEUXNQ M2Wxb2lEPTB;MTFOwG0> M{e1clI3OTN4Nki0
OCI-Ly10 MWnDfZRwfG:6aXOgRZN{[Xl? M3\Mc|czKGh? NXy2fXU3TE2VTx?= Mk\BTWM2OD1yLkC1PEDPxE1? NUnPSZM4OjV6N{izN|E>
SU-DHL2 NUDPcmRZS3m2b4TvfIlkKEG|c3H5 NV72TI9wPzJiaB?= MmP6SG1UVw>? NUjuN5EzUUN3ME2wMlAyKM7:TR?= NHy4cHgzPTh5OEOzNS=>
OCI-LY7 MVPDfZRwfG:6aXOgRZN{[Xl? NH3mZ4M4OiCq MUTEUXNQ MmrxTWM2OD1yLkC4NUDPxE1? NFLBSowzPTh5OEOzNS=>
SU-DHL6 NFrQNodEgXSxdH;4bYMhSXO|YYm= MUe3NkBp MkDjSG1UVw>? NVHpSop4UUN3ME2wMlQ5OiEQvF2= MYiyOVg4QDN|MR?=
Jeko-1 MknKR5l1d3SxeHnjJGF{e2G7 Mn63O|IhcA>? NW\BdlZsTE2VTx?= NHXReYJKSzVyPUCuNFI6KM7:TR?= M3PEe|I2QDd6M{Ox
JVM-2 MnLUR5l1d3SxeHnjJGF{e2G7 NETxRog4OiCq MXPEUXNQ NF\EfoRKSzVyPUCuNFEh|ryP NXLBUI5mOjV6N{izN|E>
Rec-1 M{Oye2N6fG:2b4jpZ{BCe3OjeR?= NVTKN5doPzJiaB?= M3nWVWROW09? M2W5OWlEPTB;MD6wPFch|ryP MUiyOVg4QDN|MR?=
Z-138 NWTYR|NiS3m2b4TvfIlkKEG|c3H5 M3fKfFczKGh? MlHuSG1UVw>? M2\UXmlEPTB;MD6wNVMh|ryP MlzpNlU5Pzh|M{G=
H9 MoPDR5l1d3SxeHnjJGF{e2G7 MYK3NkBp M13TOGROW09? NY\tOY5lUUN3ME2wMlYh|ryP M2XYXFI2QDd6M{Ox
HH NHLweVREgXSxdH;4bYMhSXO|YYm= MYC3NkBp MXHEUXNQ MYrJR|UxRTBwNzFOwG0> NI\1V5AzPTh5OEOzNS=>
DND41 Mn\BR5l1d3SxeHnjJGF{e2G7 M4noflczKGh? Mm\4SG1UVw>? NHPq[JNKSzVyPUCuNUDPxE1? M4XZZlI2QDd6M{Ox
CCL119 MXTDfZRwfG:6aXOgRZN{[Xl? MU[3NkBp M13MO2ROW09? MYTJR|UxRTBwME[yJO69VQ>? MoH2NlU5Pzh|M{G=
J.Cam 1.6 Mm\jR5l1d3SxeHnjJGF{e2G7 NFOxSoU4OiCq M1HabmROW09? MVTJR|UxRTBwMUC1JO69VQ>? MmO3NlU5Pzh|M{G=
Sup-T1 NEjVbpBEgXSxdH;4bYMhSXO|YYm= MVK3NkBp M17CUWROW09? NF\iU2RKSzVyPUKuNVQzKM7:TR?= M2rIZ|I2QDd6M{Ox
Tib 152 MnfDR5l1d3SxeHnjJGF{e2G7 MlSyO|IhcA>? M2\JT2ROW09? NFjwU|RKSzVyPUCuPEDPxE1? MUOyOVg4QDN|MR?=
MCF7 MX;GeY5kfGmxbjDBd5NigQ>? M1TCSVUh|ryP NV34b2Z{OjRiaB?= NV3OdHdPTE2VTx?= M17RfGlv\HWlZYOgS|IwVSCjcoLld5Q> MlXXNlU5OzR2MEG=
MDA-MB-231 NVjCWHpSTnWwY4Tpc44hSXO|YYm= MX61JO69VQ>? MmTmNlQhcA>? MofZSG1UVw>? NX;FPZptUW6mdXPld{BIOy:PIHHydoV{fA>? NX71WmRTOjV6M{S0NFE>
MCF7 M{HYT2Z2dmO2aX;uJGF{e2G7 NXm1PIVYPSEQvF2= M{\zTFI1KGh? NFG3fY9FVVOR NEjkW29F\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOS:FRFOy MVGyOVg{PDRyMR?=
MCF7 MnzGSpVv[3Srb36gRZN{[Xl? NXjoOWEzPSEQvF2= MWmyOEBp NXr0bFhNTE2VTx?= NVnwdYhSTGWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJGNFUzJ? NF;NdXAzPTh|NESwNS=>
MCF7 NEPYN|NHfW6ldHnvckBCe3OjeR?= Mm[3OUDPxE1? NXzmXm5vOjRiaB?= NH76[4ZFVVOR NWezZpQ3TGWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJIN6[2yrbjDCNS=> MVWyOVg{PDRyMR?=
MCF7 MV\GeY5kfGmxbjDBd5NigQ>? M1y5VVUh|ryP MkTXNlQhcA>? M2nFW2ROW09? NX\6RoZTUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJAzOSCZYX[xM2NqeDF? NWrRdo5ZOjV6M{S0NFE>
MCF7 NFPUV2FHfW6ldHnvckBCe3OjeR?= NIfwNZg2KM7:TR?= NHXCSY0zPCCq NX7sRYcyTE2VTx?= M1vGVWlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlchU2myMR?= MkLJNlU5OzR2MEG=
MDA-MB-231 MWjGeY5kfGmxbjDBd5NigQ>? NYHhO2U{PSEQvF2= M3XQTVI1KGh? MWTEUXNQ NHvmZotF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOS:FRFOy NHK2fFMzPTh|NESwNS=>
MDA-MB-231 NVzKbG1iTnWwY4Tpc44hSXO|YYm= M2[xSlEh|ryP Mn\lNlQhcA>? NEWxZo5FVVOR NVywdZVxUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJGNFUzJ? NYK4WoVnOjV6M{S0NFE>
MDA-MB-231 NXPSVodxTnWwY4Tpc44hSXO|YYm= MWW1JO69VQ>? MVuyOEBp MVPEUXNQ NYL2OYFmTGWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJIN6[2yrbjDCNS=> M4PGbVI2QDN2NECx
MDA-MB-231 MoXnSpVv[3Srb36gRZN{[Xl? NHy5NFY2KM7:TR?= MUiyOEBp NYWzUo9XTE2VTx?= MlvwTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE> NYXYXoZSOjV6M{S0NFE>
MDA-MB-231 NGXvVFFHfW6ldHnvckBCe3OjeR?= M2LvXFUh|ryP M2TYT|I1KGh? NH;BWWhFVVOR MVPJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEK3JGtqeDF? M2PPXVI2QDN2NECx
MDA-MB-231 MmS1SpVv[3Srb36gRZN{[Xl? MYe1JO69VQ>? M1zHOVI1KGh? NGXaTYlFVVOR NYj3b5JoUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJA2Ow>? MkTBNlU5OzR2MEG=
MCF7 NVzpUYFUSXCxcITvd4l{KEG|c3H5 NVq1bJU1PSEQvF2= NX:2cVZ4OjRiaB?= NF;t[JRFVVOR M4jtdmlv\HWlZYOgZZBweHSxdHnjJIRm[XSq MU[yOVg{PDRyMR?=
MDA-MB-231 NFfyTG9CeG:ydH;zbZMhSXO|YYm= M4PUNlUh|ryP MV6yOEBp MkDrSG1UVw>? NX7XZ|A6UW6mdXPld{BieG:ydH;0bYMh\GWjdHi= M4jxSFI2QDN2NECx
MCF7 NYrIUHVnTnWwY4Tpc44hSXO|YYm= NEDLXlQyKM7:TR?= NXnsOm15PzJiaB?= NI\FTJdFVVOR M{e5UGlv\HWlZYOgZZV1d3CqYXfpZ{Bl\WG2aB?= MViyOVg{PDRyMR?=
MDA-MB-231 NH3PWZlHfW6ldHnvckBCe3OjeR?= NVPBbId{OSEQvF2= NVi0cJVTPzJiaB?= M1z4Z2ROW09? MorjTY5lfWOnczDheZRweGijZ3njJIRm[XSq NGfX[40zPTh|NESwNS=>
U-2 OS NWrWcJU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXW1NI1mPTBizszN MYWyOEBp NH;RSoZFVVOR MmTRTWM2OD1zNj62JO69VQ>? NHvEW4czPTd7MkixNS=>
MG-63 MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37Mb|UxKM7:TR?= NV\4N5Y{OjRiaB?= M3TkTWROW09? MmnJTWM2OD17LkWg{txO NWO0TWZROjV5OUK4NVE>
U-2 OS MkXmRZBweHSxc3nzJGF{e2G7 NWPSZoxJPSEQvF2= MmXnNlQhcA>? NUSxWXJMTE2VTx?= MWTJcoR2[2W|IHHwc5B1d3SrYzDj[YxtKGSnYYTo NFzYb4QzPTd7MkixNS=>
MG-63 MoPhRZBweHSxc3nzJGF{e2G7 NUHyb5g6PSEQvF2= Mn;5NlQhcA>? MkG0SG1UVw>? MlXXTY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bC=> NGC4SHkzPTd7MkixNS=>
U-2 OS MVzGeY5kfGmxbjDBd5NigQ>? M3XiblUh|ryP MYCyOEBp NXPhS5kxTE2VTx?= MX3Qdo9ud3SnczDheZRweGijZ3njJINmdGxiZHXheIg> M1;oTVI2Pzl{OEGx
MG-63 NV\we41OTnWwY4Tpc44hSXO|YYm= NWjQR5lXPSEQvF2= NEPmfFQzPCCq M3[1V2ROW09? Ml\TVJJwdW:2ZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp NV3heJFZOjV5OUK4NVE>
PANC-1 M4fTOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXaOVAh|ryP MormNlQhcA>? MYjEUXNQ NYTqXGFmUUN3ME23MlEh|ryP MXOyOVY{OjJ{NR?=
BxPC-3 M2fieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HSZlUxKM7:TR?= MViyOEBp NHP0R5pFVVOR MmTPTWM2OD14Lkig{txO M1e3NVI2PjN{MkK1
PANC-1 MWLGeY5kfGmxbjDBd5NigQ>? NXnROWxyPSEQvF2= NEfoW20zPCCq M2C4NWROW09? MYnJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJGczN01icHjhd4U> NIPGSm8zPTZ|MkKyOS=>
BxPC-3 NHrpWFJHfW6ldHnvckBCe3OjeR?= MnjVOUDPxE1? NUXKTY9[OjRiaB?= Mk\ESG1UVw>? MWDJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJGczN01icHjhd4U> M3XGelI2PjN{MkK1
PANC-1 NFj2RXlHfW6ldHnvckBCe3OjeR?= NWnD[HdTPSEQvF2= M1LXTFI1KGh? NYD5S5VpTE2VTx?= MXvJcoR2[2W|IHH1eI9xcGGpaXOgZ4VtdCCmZXH0bC=> MljqNlU3OzJ{MkW=
BxPC-3 MW\GeY5kfGmxbjDBd5NigQ>? MVG1JO69VQ>? MWWyOEBp MnPzSG1UVw>? NF3PeVNKdmS3Y3XzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>? NHfRZ2IzPTZ|MkKyOS=>
SKOV3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7SNVAxKM7:TR?= NWPoR2ZtOjRiaB?= NX2wTmh3TE2VTx?= M4W2bGlEPTB;MkCuOFgh|ryP NIrMUoIzPTZ{NEe1NC=>
OVCAR4 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmi0NVAxKM7:TR?= NWOyOmZ5OjRiaB?= MVTEUXNQ M2X4c2lEPTB;MkKuNVMh|ryP MWqyOVYzPDd3MB?=
SKOV3 Mn;3SpVv[3Srb36gRZN{[Xl? M3S1cFUh|ryP MV:3NkBp NHjy[HZFVVOR MU\JcoR2[2W|IFeyM20h[XK{ZYP0 NV:5Rld7OjV4MkS3OVA>
OVCAR4 MVzGeY5kfGmxbjDBd5NigQ>? MXW1JO69VQ>? MknHO|IhcA>? MoPSSG1UVw>? M120Umlv\HWlZYOgS|IwVSCjcoLld5Q> NHvtS4MzPTZ{NEe1NC=>
SKOV3 NVG3RVlESXCxcITvd4l{KEG|c3H5 NGXMXXg2KM7:TR?= MYOyOEBp M4\W[mROW09? M2fvV2lv\HWlZYOgZZBweHSxc3nz MoK0NlU3OjR5NUC=
OVCAR4 MULBdI9xfG:|aYOgRZN{[Xl? MkDlOUDPxE1? NWTVNHBmOjRiaB?= M3v1RmROW09? NXXFZoxIUW6mdXPld{BieG:ydH;zbZM> MUiyOVYzPDd3MB?=
AGS M2jiT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjMe|IzPSEQvF2= MkHuNlQhcA>? NV:xVnFxTE2VTx?= NX;DV2doUUN3ME2xPU4xQSEQvF2= NWnJb4szOjV4MEm5NlM>
NCI-N78 MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7uc3AzPSEQvF2= MkPXNlQhcA>? NVLXVY1YTE2VTx?= M3rmbWlEPTB;Mk[uN|Mh|ryP NUDzfodoOjV4MEm5NlM>
AGS MoDORZBweHSxc3nzJGF{e2G7 MlTyOUDPxE1? MX:yOEBp NHz0cmhFVVOR MkjLTY5lfWOnczDhdI9xfG:|aYO= Mmf5NlU3ODl7MkO=
NCI-N78 MknVRZBweHSxc3nzJGF{e2G7 M4i0VlUh|ryP M4nDbFI1KGh? NITUS21FVVOR NGSzeWZKdmS3Y3XzJIFxd3C2b4Ppdy=> NUnxOJpuOjV4MEm5NlM>
AGS M2X2b2Z2dmO2aX;uJGF{e2G7 M4nNSVUh|ryP NVHjZ5FQOjRiaB?= M{m4R2ROW09? NU\0TopzUW6mdXPld{B1cGViYYX0c5Bp[We7 MXmyOVYxQTl{Mx?=
NCI-N78 MnO2SpVv[3Srb36gRZN{[Xl? NWnCdYV6PSEQvF2= M2Cw[VI1KGh? NXXVfYdzTE2VTx?= NUn2VJdlUW6mdXPld{B1cGViYYX0c5Bp[We7 MXmyOVYxQTl{Mx?=
HSC-3 NVfl[|lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqxJO69VQ>? MlH1OFghcA>? MVPJR|UxRTBwNUSg{txO M4jnU|I2OzZ4MUSz
GB30 M2ToXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rjc|Eh|ryP NXezV2lMPyCm MWfEUXNQ M2C2UGlEPTB;MD6wNVEh|ryP M1vafVI2OTB4NEK4
GB9 NYTFOZpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfa[ZYyKM7:TR?= MUm3JIQ> MmDNSG1UVw>? MVHJR|UxRTBwMEK0JO69VQ>? M4HGRVI2OTB4NEK4
GB169 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFG4cVUyKM7:TR?= NUmxUFJoPyCm MYTEUXNQ NHTNb4ZKSzVyPUCuNFMzKM7:TR?= Mm\ZNlUyODZ2Mki=
T24 M{D6cmZ2dmO2aX;uJGF{e2G7 NET6VnMyKM7:TR?= MUe0PEBp MWPEUXNQ M2f6e2lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= NU\IO4xqOjN2MEO2N|M>
RT4 NG\4OGtHfW6ldHnvckBCe3OjeR?= NWHMVXNVOSEQvF2= MoHEOFghcA>? NUDudGRKTE2VTx?= NX3hWFV7UW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> M4PtdlI{PDB|NkOz
UM-UC-3 MWfGeY5kfGmxbjDBd5NigQ>? MYmxJO69VQ>? M{nqfFQ5KGh? Ml3iSG1UVw>? NXjjNFhLUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> MmrjNlM1ODN4M{O=
T24 MWjBdI9xfG:|aYOgRZN{[Xl? M17DVFMvOTZizszN MUC5OkBp NXThW44xTE2VTx?= MnXlTWM2OD1yLkCzNFYh|ryP M{T6S|I{PDB|NkOz
RT4 NFrLfIpCeG:ydH;zbZMhSXO|YYm= M3nFN|MvOTZizszN NVLKXGJSQTZiaB?= MYPEUXNQ M174dmlEPTB;MD6xNVk5KM7:TR?= NWHucVE2OjN2MEO2N|M>
UM-UC-3 MULBdI9xfG:|aYOgRZN{[Xl? MWizMlE3KM7:TR?= NFHDdGw6PiCq NIHNR|VFVVOR MX\JR|UxRTBwMES0PUDPxE1? MlTzNlM1ODN4M{O=
OVCAR-5 NVfJZZpsTnWwY4Tpc44hSXO|YYm= M4W4V|UxKG6P NIDhTlhKdmirYnn0d{Bk\WyuIH3p[5JifGmxbh?= NYTRVW1ROjN|M{SzNlc>
SKOV3ip2 M4THfGZ2dmO2aX;uJGF{e2G7 NFvNVI82OCCwTR?= NXvnb|JFUW6qaXLpeJMh[2WubDDtbYdz[XSrb36= NVK1VnVDOjN|M{SzNlc>
S462 MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17ueVExOCEQvF2= NHnQWGQ4OiCq M3y0N2ROW09? M{LIVGF1fGWwdXH0[ZMh[2WubDDndo94fGh? M3ewclI{OzJ6MUG0
2884 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjQPYwyODBizszN MkLDO|IhcA>? MkTvSG1UVw>? NVXTPIxHSXS2ZX71ZZRmeyClZXzsJIdzd3e2aB?= NYK1cFNrOjN|MkixNVQ>
2885 M3TR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{e4WVExOCEQvF2= M3PtUVczKGh? M{LIRmROW09? MoSzRZR1\W63YYTld{Bk\WyuIHfyc5d1cA>? MYqyN|MzQDFzNB?=
CRL-2396 NE\DZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[xNFAh|ryP NV\JV2x1f2G2ZYK= MkTLTWM2OD1yLkC5NkDPxE1? MXGyN|E2OzV{NB?=
TIB-48 MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUSxNFAh|ryP M{T6TpdifGW{ MkDOTWM2OD1yLkC4PEDPxE1? NWjic21oOjNzNUO1NlQ>
CRL-2396 MmC1R5l1d3SxeHnjJGF{e2G7 MVSxJO69VQ>? NFfS[nI1QCCq M2TJeJdifGW{ M3vuZWlv\HWlZYOgZZBweHSxc3nz M4P2TlI{OTV|NUK0
TIB-48 NWm5[ldpS3m2b4TvfIlkKEG|c3H5 M3\5eFEh|ryP MkLyOFghcA>? M3jvbpdifGW{ MlvyTY5lfWOnczDhdI9xfG:|aYO= NHP5bo8zOzF3M{WyOC=>
AGS NYPBU4E4S3m2b4TvfIlkKEG|c3H5 NXfBXotMOC53IN88US=> NH\IZ5gzPCCq NGG2PJpFVVOR MlvHSIVkemWjc3XzJINmdGxic4Xyeol3[Wx? NVzKbYFNOjJ7N{K2NVE>
FLO-1 Mn7JR5l1d3SxeHnjJGF{e2G7 NGrGPVUxNjVizszN NGHmSFQzPCCq MWjEUXNQ NH;qZmZF\WO{ZXHz[ZMh[2WubDDzeZJ3cX[jbB?= NF3tfY4zOjl5Mk[xNS=>
OE33 MX7DfZRwfG:6aXOgRZN{[Xl? NHLuWWcxNjVizszN MXuyOEBp M2ewdWROW09? MmX5SIVkemWjc3XzJINmdGxic4Xyeol3[Wx? NHTZ[FUzOjl5Mk[xNS=>
SKLMS NHnLTpJEgXSxdH;4bYMhSXO|YYm= NEToc2k4PSCwTR?= M4nnWFk3KGh? MXrJcoR2[2W|IHHwc5B1d3Orcx?= NWDJTXpqOjJ6MkG5PVc>
Leio285 MXHDfZRwfG:6aXOgRZN{[Xl? M2H1[|c2KG6P NFLqZ4E6PiCq MlLoTY5lfWOnczDhdI9xfG:|aYO= NITCW|AzOjh{MUm5Oy=>
Mes-Sa MX\DfZRwfG:6aXOgRZN{[Xl? NWrvfXhoPzVibl2= MnrDPVYhcA>? M3TBeWlv\HWlZYOgZZBweHSxc3nz NGHEZogzOjh{MUm5Oy=>
DAOY NWHKTY5RS3m2b4TvfIlkKEG|c3H5 MnPRNVAh|ryP M4K1[FczKGh? MkHVSG1UVw>? NUewb5ZRUUN3ME2wMlA1KM7:TR?= MWKyNlY3QTN|NR?=
IMR32 M2PCNmN6fG:2b4jpZ{BCe3OjeR?= NGTm[nQyOCEQvF2= Mkm1O|IhcA>? MkX4SG1UVw>? MkPPTWM2OD1yLkCzJO69VQ>? M3mxblIzPjZ7M{O1
Molt-4 MYfDfZRwfG:6aXOgRZN{[Xl? M3fBN|ExKM7:TR?= M1vafFczKGh? NIi5NJZFVVOR Moq1TWM2OD1yLkCyJO69VQ>? MWWyNlY3QTN|NR?=
MOLM-13 MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnkNlY{KM7:TR?= NGfBcmo4OiCq M{\GbmRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= MWeyNlQ5QDJ2OR?=
HL-60 M1fZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVizJO69VQ>? NIDiWW04OiCq NVfQeIpOTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> M1nYfVIzPDh6MkS5
MV4-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqzJO69VQ>? NUPKWZVmPzJiaB?= MUHEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 MVKyNlQ5QDJ2OR?=
SKM-1 NXfQUIpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TM[|Mh|ryP MYG3NkBp MkjuSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NHTiNHQzOjR6OEK0PS=>
SH2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HXV|Mh|ryP Mk\WO|IhcA>? NG\QXI5FcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 NGjsdJczOjR6OEK0PS=>
NOMO-1 MnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULDdnZIOyEQvF2= NWHEZXVWPzJiaB?= Mn6xSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= M3vVdlIzPDh6MkS5
OCL-AML2 MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL6OIptOyEQvF2= Ml7TO|IhcA>? NUexU2NMTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> MX2yNlQ5QDJ2OR?=
PL-21 NGP3eWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[zJO69VQ>? NGTHNHA4OiCq MkD4SIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NEm0fYQzOjR6OEK0PS=>
KG-1 M2nUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSzJO69VQ>? M3f4PFczKGh? NH24U3ZFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 M1nqUFIzPDh6MkS5
A172 NGnoRZlEgXSxdH;4bYMhSXO|YYm= NI[1XmsyODBizszN Mk[1NlQhcA>? MYLEUXNQ MUXJR|UxRTBwMUKwJO69VQ>? NVnMOW1wOjJ{N{SzPVk>
U87 MXvDfZRwfG:6aXOgRZN{[Xl? NUTwcZpuOTByIN88US=> M{LNbVI1KGh? NV\jdZRSTE2VTx?= MY\JR|UxRTBwMUC1JO69VQ>? NXzLcWNLOjJ{N{SzPVk>
U251 M3XGc2N6fG:2b4jpZ{BCe3OjeR?= NIT1eG4yODBizszN MXOyOEBp MXTEUXNQ NFLUWppKSzVyPUCuNVAxKM7:TR?= M4nKSFIzOjd2M{m5
T98 M1jCU2N6fG:2b4jpZ{BCe3OjeR?= NV\YepYzOTByIN88US=> MoLVNlQhcA>? MnLkSG1UVw>? NHi4[W9KSzVyPUCuNVI2KM7:TR?= MVyyNlI4PDN7OR?=
LN18 NV\zc|hlS3m2b4TvfIlkKEG|c3H5 MYqxNFAh|ryP M2TkUFI1KGh? MYHEUXNQ NGjI[nNKSzVyPUCuNlExKM7:TR?= MWiyNlI4PDN7OR?=
LN443 NYDIUpVJS3m2b4TvfIlkKEG|c3H5 NFTzXVEyODBizszN NVniU2VGOjRiaB?= NGfu[oNFVVOR NVq0coFJUUN3ME2wMlIzOCEQvF2= MXGyNlI4PDN7OR?=
HF66 NGLVeVVEgXSxdH;4bYMhSXO|YYm= NG\UUocyODBizszN NVPzS3lIOjRiaB?= NU\sZYxrTE2VTx?= M2PmZWlEPTB;MD6yNlUh|ryP MnrSNlIzPzR|OUm=
HF2303 NELuWJBEgXSxdH;4bYMhSXO|YYm= NXu3b4tiOTByIN88US=> MV2yOEBp M3roSWROW09? MkXyTWM2OD1yLkC2NEDPxE1? MmfCNlIzPzR|OUm=
HF2359 NGXN[WZEgXSxdH;4bYMhSXO|YYm= NGSyd2oyODBizszN MX6yOEBp NY\tc2dRTE2VTx?= NWPEbHBxUUN3ME2wMlA3OCEQvF2= NV62ZopCOjJ{N{SzPVk>
HF2414 M{fMemN6fG:2b4jpZ{BCe3OjeR?= NX;lfnhLOTByIN88US=> M323Z|I1KGh? NUDHcpA{TE2VTx?= M33l[GlEPTB;MD6wPFAh|ryP Mn\2NlIzPzR|OUm=
A-673 NYrNOo5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXBPWV1OTBizszN MVu5OkBp NFjmUmxFVVOR MlTUTWM2OD1yLkCzNkDPxE1? NXzDXnI2OjF2NEi1PVE>
TC-32 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzyNVAh|ryP M4\2Vlk3KGh? MmrtSG1UVw>? MYrJR|UxRTBwMEO5JO69VQ>? NF\rUG8zOTR2OEW5NS=>
TC-71 MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXexNEDPxE1? M{nkb|k3KGh? MU\EUXNQ MoLHTWM2OD1yLkGwNkDPxE1? M13wTVIyPDR6NUmx
SK-N-MC NVTYbJZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fQWlExKM7:TR?= M3y4Nlk3KGh? MVXEUXNQ MoHjTWM2OD1yLkC3NkDPxE1? MUKyNVQ1QDV7MR?=
CHLA-9 NITJc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fxPFExKM7:TR?= NV35XJNWQTZiaB?= NGK3fHRFVVOR MVfJR|UxRTBwMEG4JO69VQ>? MX2yNVQ1QDV7MR?=
CHLA-10 NGD5dFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P4dlExKM7:TR?= MmfuPVYhcA>? MnuxSG1UVw>? MorJTWM2OD1yLkC2NEDPxE1? NHzXXlYzOTR2OEW5NS=>
CHLA-25 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfQPJBQOTBizszN M1zOPFk3KGh? NGnGcY5FVVOR NH;IbWZKSzVyPUCuNVY5KM7:TR?= MY[yNVQ1QDV7MR?=
CHLA-32 Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jDb|ExKM7:TR?= NUPOSZV6QTZiaB?= MnHtSG1UVw>? NX7t[49JUUN3ME2wMlE{PiEQvF2= MnSzNlE1PDh3OUG=
CHLA-56 NYDBNItJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTWNVAh|ryP MkTKPVYhcA>? MonxSG1UVw>? M3riS2lEPTB;MUCg{txO M1Xlc|IyPDR6NUmx
CHLA-258 MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULhTGNSOTBizszN NFTCeZg6PiCq MmnrSG1UVw>? MVnJR|UxRTBwMUOyJO69VQ>? MY[yNVQ1QDV7MR?=
COG-E-352 M2Tlc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYexNEDPxE1? M4nkRlk3KGh? NHjJWYhFVVOR NXS0doRmUUN3ME2wMlA1OyEQvF2= M33BZ|IyPDR6NUmx
CHLA-90 NXLVN5g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPkWFYyOCEQvF2= MVS5OkBp NFjpUpNFVVOR MojjTWM2OD1yLkC2NUDPxE1? NFXRcJczOTR2OEW5NS=>
CHLA-119 M{fNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4OxSFExKM7:TR?= MXi5OkBp MnjISG1UVw>? M4rtW2lEPTB;MD6wNlIh|ryP Mlr2NlE1PDh3OUG=
CHLA-122 NF\6[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rkelExKM7:TR?= NFzBdoU6PiCq MWnEUXNQ M2i1cWlEPTB;MD6wNVkh|ryP MVWyNVQ1QDV7MR?=
CHLA-136 MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjufXEyOCEQvF2= NVjmTW97QTZiaB?= NUDBOoJjTE2VTx?= NF\YWWJKSzVyPUCuNFM6KM7:TR?= M2TR[|IyPDR6NUmx
CHLA-140 M{XsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;RTGoyOCEQvF2= Ml75PVYhcA>? MYnEUXNQ M{PVZmlEPTB;MD6wNlYh|ryP MmrPNlE1PDh3OUG=
LA-N-6 MlrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3xNVAh|ryP Ml62PVYhcA>? MoLZSG1UVw>? NX;k[W5zUUN3ME2wMlA2PCEQvF2= NIKz[IszOTR2OEW5NS=>
NB-1643 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfINVAh|ryP NVvCfWo6QTZiaB?= Ml7xSG1UVw>? NELDOYZKSzVyPUCuNFM4KM7:TR?= M4\JOFIyPDR6NUmx
NB-EBc1 MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorRNVAh|ryP NYfDfVFRQTZiaB?= MVzEUXNQ NHP2SlJKSzVyPUCuNFUxKM7:TR?= MUOyNVQ1QDV7MR?=
SK-N-BE-1 MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PuOVExKM7:TR?= MY[5OkBp MnXoSG1UVw>? NIPyb3dKSzVyPUCuNFI5KM7:TR?= NX;IbZVDOjF2NEi1PVE>
SK-N-BE-2 NFP0OYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrJZW9qOTBizszN NUHMcZJxQTZiaB?= M1LlZ2ROW09? MVvJR|UxRTBwMEO2JO69VQ>? MWWyNVQ1QDV7MR?=
SMS-KAN Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUOxNEDPxE1? MYm5OkBp MoXmSG1UVw>? NX3JNYZLUUN3ME2wMlA{PCEQvF2= MX[yNVQ1QDV7MR?=
SMS-KANR M1zRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLOSox4OTBizszN Mo\hPVYhcA>? MnH6SG1UVw>? NHjsTVlKSzVyPUCuNFI3KM7:TR?= MlvhNlE1PDh3OUG=
SMS-KCN MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvY[GNrOTBizszN NYrhVYJQQTZiaB?= NEfyRXZFVVOR NGjoemtKSzVyPUCuNFE6KM7:TR?= M17Ve|IyPDR6NUmx
SMS-KCNR MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;KNVAh|ryP MVW5OkBp MUDEUXNQ M{Hue2lEPTB;MD6wNVAh|ryP MnHMNlE1PDh3OUG=
SMS-LHN M{fBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXuxNEDPxE1? NU\ZeZpYQTZiaB?= M4jGWGROW09? M3HG[GlEPTB;MD6wN|Ih|ryP NUHGWZV4OjF2NEi1PVE>
SMS-MSN MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPR[m1iOTBizszN NV;Qeoh6QTZiaB?= M{LCb2ROW09? NETzb3hKSzVyPUCuNFIzKM7:TR?= M3TrdVIyPDR6NUmx
SMS-SAN Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVuxNEDPxE1? NGfG[XI6PiCq NIC0V2hFVVOR M2PWV2lEPTB;MD6wNlAh|ryP MVmyNVQ1QDV7MR?=
Granta-4 MonkR5l1d3SxeHnjJGF{e2G7 MWKxNEDPxE1? NHHhUFY4KGR? MYLJR|UxRTBwMESwJO69VQ>? MVyyNVI6OTh4Nx?=
DB MnjSR5l1d3SxeHnjJGF{e2G7 MojlNVAh|ryP M1K4Vlch\A>? M3\NUGlEPTB;MD6wOFIh|ryP M3rPeFIyOjlzOE[3
RL MW\DfZRwfG:6aXOgRZN{[Xl? Mlr0NVAh|ryP MV63JIQ> NW\1blNvUUN3ME2wMlAyPSEQvF2= MV:yNVI6OTh4Nx?=
K562 M1fMNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKxNEDPxE1? NFizeJQ6PiCq NGfSS2dKSzVyPUCuNFg4KM7:TR?= MX:yNVA6OTZ|Mx?=
LAMA-84 M3TDdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH6xbYoyOCEQvF2= M{HadFk3KGh? M4rqWWlEPTB;MD6wOVch|ryP MWSyNVA6OTZ|Mx?=
MM15 NHv2XGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzM[nY1KM7:TR?= NIHZUoQ4OiCq NHjKdJFFVVOR MXzJR|UxRTBwMUOg{txO NFPBbJQzODN6Mki0OC=>
OPM1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fwT|Qh|ryP NIDacHc4OiCq MXXEUXNQ NX3xZotRUUN3ME2wMlA{KM7:TR?= NYnRW3pGOjB|OEK4OFQ>
RPM1 NHzJdoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYK0JO69VQ>? MX23NkBp MoGwSG1UVw>? MlLOTWM2OD1zMD6zNkDPxE1? NHn1d2wzODN6Mki0OC=>
INA6 M2j0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\ZWFQh|ryP M{XQ[VczKGh? M3zyVmROW09? M4WzWmlEPTB;MD6wNFIh|ryP NED3W5YzODN6Mki0OC=>
OPM2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXq0JO69VQ>? MUW3NkBp NF63RXdFVVOR NGiyTZNKSzVyPUSuN|ch|ryP NFfzb5UzODN6Mki0OC=>
MM1R M3GxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfR[FRWPCEQvF2= NESyb5I4OiCq MkjYSG1UVw>? MWrJR|UxRTFwNkig{txO NV7CeWFCOjB|OEK4OFQ>
DOX40 MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG2RWlrPCEQvF2= NX[y[IJmPzJiaB?= NG\1T2hFVVOR NIPrbnJKSzVyPUWuOFgh|ryP NG\Cbm0zODN6Mki0OC=>
LR5 NXO1VXN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PiOVQh|ryP MkDqO|IhcA>? M13TWGROW09? NYT5cXd5UUN3ME2yMlU{KM7:TR?= MYCyNFM5Ojh2NB?=
U266 M2fMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzoNHg1KM7:TR?= MWC3NkBp NHrucmVFVVOR NEnP[HVKSzVyPUGuOFMh|ryP NEj2fGUzODN6Mki0OC=>
RD NEnnfWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHKwdHAyOCEQvF2= MmK2PVYhcA>? NVz0bppqUUN3ME2wMlIzQCEQvF2= M{LGdVIxOTB6M{O4
Rh41 NWjlNlY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXOxNEDPxE1? NIjRS2o6PiCq NGHMNYlKSzVyPUCuNFkxKM7:TR?= NVLhWoJzOjBzMEizN|g>
Rh30 NIXNO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTFNVAh|ryP MVy5OkBp M1ruZWlEPTB;MD6yN|Ah|ryP NIGwSm0zODFyOEOzPC=>
BT-12 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUCxNEDPxE1? NFjWXYM6PiCq NYX0PJpqUUN3ME2wMlA3OCEQvF2= MUSyNFExQDN|OB?=
CHLA-266 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\QNVAh|ryP NEDWeWQ6PiCq NXHKSXc1UUN3ME2wMlA4OiEQvF2= M33VRVIxOTB6M{O4
TC-71 NXHTdXU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PwWlExKM7:TR?= MVG5OkBp M{jUXmlEPTB;MD6xNFIh|ryP MonXNlAyODh|M{i=
SJ-GBM2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nSZVExKM7:TR?= MljoPVYhcA>? NEfzS4dKSzVyPUCuNFUxKM7:TR?= NV3TWHYyOjBzMEizN|g>
NALM-6 NUTJNph{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLleWIyOCEQvF2= NWntSpdPQTZiaB?= MYLJR|UxRTBwME[yJO69VQ>? NH[0cYczODFyOEOzPC=>
COG-LL-317 MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fYbFExKM7:TR?= M{joPVk3KGh? NYHzTnFOUUN3ME2wMlA1PyEQvF2= M330NVIxOTB6M{O4
RS4-11 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTWNVAh|ryP M4fLU|k3KGh? MVjJR|UxRTBwMEG4JO69VQ>? NWXBSoVzOjBzMEizN|g>
MOLT-4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3zNVAh|ryP MonaPVYhcA>? NUjQW4pXUUN3ME2wMlAzPiEQvF2= M13mRVIxOTB6M{O4
CCRF-CEM MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX4cWMyOCEQvF2= NWq5RXRDQTZiaB?= MnXSTWM2OD1yLkC5OEDPxE1? NVfzOY1wOjBzMEizN|g>
Kasumi-1 NXXX[3k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUexNEDPxE1? NVfHN4xwQTZiaB?= NV\j[Xc{UUN3ME2wMlExOyEQvF2= MVKyNFExQDN|OB?=
Karpas-299 Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDkNVAh|ryP MWK5OkBp NGO5RnlKSzVyPUCuNFM5KM7:TR?= M3;IelIxOTB6M{O4
Ramos-RA1 Mn;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PBXlExKM7:TR?= Mm[wPVYhcA>? NWLBc4hxUUN3ME2wMlEzPyEQvF2= NGDaUpQzODFyOEOzPC=>

... Click to View More Cell Line Experimental Data

体内研究 MLN8237口服处理,显著降低肿瘤负担,按15 mg/kg 和30 mg/kg剂量处理肿瘤生长抑制率(TGI) 分别为42%和80%,且与对照组相比,延迟小鼠寿命。[2] MLN8237 (30 mg/kg) 与Cisplatin (2 mg/kg) 联用作用于FLO-1移植瘤,与单独用药相比,抗癌活性增强,伴随着Ki-67表达受抑制,细胞核p73蛋白和cleaved caspase 3表达增强。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

Aurora A放射性闪光板酶实验:

进行Aurora A放射性闪光板酶实验,测定体外MLN8237抑制程度。在Sf9细胞中表达重组Aurora A,然后使用GST亲和层析进行纯化。Aurora A 肽底物与生物素联合形成生物素-GLRRASLG。在50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween-20, 2 μM 肽底物, 3.3 μCi/mL [γ-33 P]ATP 2 μM, 和浓度不断增高的MLN8237 的混合物中进行Aurora A激酶 (5 nM)实验。
细胞实验:[2]
+ 展开
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, 和U266
  • Concentrations: 溶于DMSO,终浓度为~10 μM
  • Incubation Time: 24, 48, 和72小时
  • Method: 使用不同浓度MLN8237处理细胞24, 48,和72小时。通过MTT实验测定细胞活力,通过测定 3[3H]-胸甘渗透而测定细胞增殖。为了分析细胞周期,使用70%乙醇在-20oC下使细胞通透,然后与50 μg/mL PI 和20 单位/mL RNase-A温育。 通过流式细胞仪使用 BDFACS-Canto II和FlowJo软件分析DNA含量。 为了测定凋亡和衰老,使用异硫氰酸荧光素-annexin V和PI对细胞进行染色。通过流式细胞仪使用 BDFACS-Canto II和FlowJo软件测定凋亡细胞。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 皮下接种 MM1.S 细胞的SCID鼠
  • Formulation: 在10% 2-羟丙基-β-环糊精/1%碳酸氢钠中配制
  • Dosages: ~30 mg/kg/day
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 27 mg/mL (52.03 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5%DMSO+30% PEG300+5%Tween-80+ddH2O
8mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 518.92
化学式

C27H20ClFN4O4

CAS号 1028486-01-2
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01924260 Active not recruiting Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unspecified Adult Solid Tumor Protocol Specific University of California Davis|National Cancer Institute (NCI)|Takeda August 9 2013 Phase 1
NCT01397825 Completed Diffuse Large B-Cell Lymphoma|Transformed Follicular Lymphoma|Mantle Cell Lymphoma|Burkitt''s Lymphoma Millennium Pharmaceuticals Inc.|Takeda August 9 2011 Phase 1|Phase 2
NCT01677559 Completed Adenocarcinoma|Pancreatic Neoplasms Washington University School of Medicine May 7 2013 Phase 1
NCT00697346 Completed B-cell Follicular Lymphoma|B-cell Marginal Zone Lymphoma|Diffuse Large B-cell Lymphoma|B-cell Mantle Cell Lymphoma|B-cell Small Lymphocytic Lymphoma (SLL)|B-Cell Chronic Lymphocytic Leukemia (B-CLL)|Multiple Myeloma|Waldenstrom''s Macroglobulinemia|Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified (PTCL-NOS)|Angioimmunoblastic T-cell Lymphoma (AITL)|Anaplastic Large Cell Lymphoma|Enteropathy Associated T-cell Lymphoma (EATCL)|NK Lymphoma (NKL) Millennium Pharmaceuticals Inc.|Takeda October 7 2008 Phase 1
NCT02860000 Recruiting Estrogen Receptor Status|HER2/Neu Negative|Invasive Breast Carcinoma|Postmenopausal|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) July 6 2017 Phase 2
NCT02219789 Completed Estrogen Receptor Positive|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 5 2014 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • 回答:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

相关Aurora Kinase产品

Tags: 购买Alisertib (MLN8237) | Alisertib (MLN8237)供应商 | 采购Alisertib (MLN8237) | Alisertib (MLN8237)价格 | Alisertib (MLN8237)生产 | 订购Alisertib (MLN8237) | Alisertib (MLN8237)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID